Kava
Kava (ʻawa, Piper methysticum)
Evidence grade varies by use. See the breakdown on the entry. Read how the Atlas grades evidence.
For short-term anxiety, the trial literature is, by the account of its own reviewers, relatively well developed for a traditional botanical, which supports grade 3 (emerging to moderate human data) rather than higher. A Cochrane systematic review (Pittler and Ernst, 2003) pooled double-blind randomized placebo-controlled trials of kava extract for anxiety; the authors reported a significant reduction on the Hamilton Anxiety Rating Scale in the pooled trials. The reviewers themselves cautioned that the effect lacked robustness and rested on small samples, and called for larger, longer trials. Adverse events in those trials were described as mild and transient, with no hepatotoxic events reported in the trial populations. Later dedicated trials, including the Australian Kava Anxiety Depression Spectrum work and a larger generalized anxiety disorder (K-GAD) trial, produced mixed results, with at least one larger generalized anxiety disorder trial failing to separate kava from placebo. Net read: a real short-term anxiolytic signal that is modest and uneven, well short of guideline-endorsed first-line status.
Reference only. Not medical advice.
| Treatment | Grade | Notes |
|---|---|---|
| Short-term generalized anxiety symptoms | 3 of 5 | The 2003 Cochrane meta-analysis of multiple RCTs reports a significant HAM-A reduction, but the reviewers note the effect lacks robustness and samples are small, and a later larger GAD trial was negative. |
| Insomnia and stress-related restlessness | 2 of 5 | Limited and preliminary trial data; sedative effects are reported but anxiety-specific trials dominate the literature. |
| Ceremonial and social use (relaxation, sociability) | 2 of 5 | Centuries of consistent traditional use document the calming, sociable effect; this is experiential and ethnographic, not controlled-trial, evidence. |
| Depression | 1 of 5 | Theory and some spectrum-trial interest outpace evidence; kava is not established as an antidepressant. |
What can go wrong
The dominant safety concern is rare but serious liver injury (hepatotoxicity), including reports of hepatitis, cirrhosis, and liver failure that drove regulatory bans starting in 2002. Reported risk with properly prepared product appears low, but it is not zero and can be severe. Risk concentrates around poor-quality raw material, use of aerial parts (leaves and stems) and non-noble two-day (tudei) cultivars, solvent-based extracts, and concurrent alcohol or other liver-stressing drugs. Kava can also cause a reversible scaly skin condition (kava dermopathy) with heavy chronic use, and may impair driving and potentiate sedatives. People with liver disease, those drinking alcohol, pregnant or breastfeeding people, and anyone on hepatically metabolized medications should avoid kava or seek clinical guidance.
This is something to take to a clinician. The Atlas can tell you what is known about kava in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Kava is the pounded root of Piper methysticum, a sterile crop bred by Melanesian farmers in northern Vanuatu about 3,000 years ago and carried across the Pacific by Austronesian voyagers, where it became central to ceremony, diplomacy, and worship from Fiji and Tonga to Hawaii. Drunk traditionally as a water-based infusion, it produces a calm, sociable, mildly numbing state attributed to kavalactones acting largely through GABA-A modulation. By the account of its systematic reviewers, kava has one of the more developed short-term anxiety evidence bases among traditional botanicals: a 2003 Cochrane review of double-blind randomized trials reported a significant reduction in anxiety symptoms, though the reviewers stressed the effect was modest and the samples small, and a later larger trial was negative. That moderate promise is shadowed by rare reports of serious liver injury, which prompted Germany to ban ethanolic and acetonic extracts in 2002. A German Administrative Court overturned that ban in 2014, and much of the field has since coalesced around the view that product quality, cultivar, plant part, and preparation method, rather than kava itself, drive most harm. Kava remains legal as a dietary supplement in the United States, is regulated with kavalactone dose caps in Australia, and in 2025 was affirmed by Hawaii as a traditional Native food.
A sterile, human-bred Pacific root pounded into a numbing, calming ceremonial drink, carrying about 3,000 years of Oceanic protocol and, by the account of its systematic reviewers, one of the more developed evidence bases for short-term anxiety relief among traditional botanicals.
How it is supposed to work
Established: kava's active constituents are a family of lipid-soluble lactones called kavalactones (notably kavain, dihydrokavain, methysticin, and yangonin), concentrated in the root and rhizome. Human and laboratory work shows kavalactones produce measurable central nervous system effects and oral numbing, consistent with anxiolytic and mild sedative action. Proposed and not fully settled: the favored model is positive modulation of GABA-A receptor signaling, with additional reported actions including blockade of voltage-gated sodium and calcium channels, monoamine oxidase B inhibition, and effects on dopamine and noradrenaline pathways. Which of these dominates the anxiety effect in humans is not resolved, and the exact receptor binding picture differs from that of benzodiazepines.
What people get wrong
Often saidKava is just a natural sedative with no real evidence behind it.
ActuallyIts systematic reviewers describe one of the more developed short-term anxiety evidence bases among traditional botanicals; a 2003 Cochrane review of double-blind RCTs reported a significant, if modest, anxiety reduction, while later trials were mixed.
Often saidKava was proven to destroy the liver, which is why it was banned.
ActuallySerious liver injury is real but rare and, per the researchers studying it, tied largely to product quality and preparation; Germany's 2002 ban on certain extracts was overturned by a German court in 2014 as disproportionate.
Who profits, and who pushes back
Cochrane reviewers (Pittler and Ernst)
Kava extract is an effective symptomatic treatment for anxiety, although the effect lacks robustness and is based on a relatively small sample; larger and longer trials are needed.
Mathias Schmidt
The hepatotoxicity attributed to kava reflects ill-defined herbal identity and lacking quality control more than an inherent danger of the properly prepared root.
U.S. NCCIH
Kava may help with anxiety, but it has been linked to a risk of severe liver damage, so caution is warranted.
Pacific kava-bar and supplement vendors
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Noble water-prepared kava offers a calm, social, sober alternative rooted in centuries of Pacific tradition.
Where the research comes from
Most of the published research on this comes from one place. 100% of it is from Pacific Islands (Vanuatu, Fiji, Tonga, Samoa). Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Pacific Islands (Vanuatu, Fiji, Tonga, Samoa) | 100% |
| Hawaii and US Pacific | 70% |
| Australia and New Zealand | 55% |
| United States (mainland kava bars) | 50% |
| Europe | 30% |
How we got here
Kava begins in northern Vanuatu, where Melanesian farmers domesticated Piper methysticum roughly 3,000 years ago by selectively cultivating the wild progenitor Piper wichmannii. The resulting plant is seedless and sterile, propagated only by stem cuttings, which marks it as an entirely human-made crop rather than a wild gather. Austronesian-speaking Lapita voyagers carried kava eastward into Remote Oceania between about 3,200 and 2,500 years ago, seeding the cultivars and ceremonial protocols later documented in Fiji, Tonga, Samoa, and the Hawaiian Islands, where it is called ʻawa. Across these societies the prepared drink anchored chiefly councils, peacemaking, welcome rites, and offerings to ancestors and gods. European naturalists first recorded it during James Cook's Pacific voyages in the 1770s, but that account is a late footnote to a tradition already millennia deep.
Kava's documented history runs through the oral and ceremonial traditions of Oceania long before any written record. After domestication in northern Vanuatu around 1000 BCE, kava traveled with Lapita-culture seafarers across Melanesia and into Polynesia and parts of Micronesia, accumulating distinct cultivars and ceremonial rules in each society. In Fiji it became yaqona, served in formal sevusevu presentation; in Tonga and Samoa it structured chiefly and welcome ceremonies; in Hawaii ʻawa was offered to deities and used by healers. European contact in the late 18th century, via Cook's voyages, brought outside description and eventually commercial extraction. The modern arc turned sharply in 2002, when reports linking kava to liver injury led Germany's BfArM and then several other authorities to ban or restrict it. A twelve-year legal and scientific contest followed, ending in 2014 when a German court overturned the ban as disproportionate. Pacific nations meanwhile reasserted control: Vanuatu legislated to protect noble cultivars, and exports and a global kava-bar culture expanded into the 2020s.
- c.1000 BCEMelanesian farmers in northern Vanuatu domesticate Piper methysticum from wild Piper wichmannii
- c.1200 BCE to 500 BCELapita and Austronesian voyagers spread kava across Remote Oceania to Fiji, Tonga, Samoa, and Hawaii
- 2002Germany's BfArM bans ethanolic and acetonic kava extracts after hepatotoxicity reports; other authorities follow
- 2003Cochrane review of double-blind randomized trials reports a significant short-term anxiety effect with cautions on robustness
- 2014German Administrative Court overturns the 2002 kava ban as disproportionate
- 2025Hawaii affirms ʻawa as a traditional Native food; FDA clarifies kava-and-water tea as a single-ingredient conventional food
How it is understood
Kava is a living ceremonial and social institution, not a generic relaxant. In Fiji, Tonga, Samoa, Vanuatu, and Hawaii the drink is prepared, served, and consumed within specific protocols of rank, sequence, and speech, and the plant itself is woven into genealogy, statecraft, and worship. Vanuatu treats noble kava cultivars as national patrimony and regulates which varieties may be exported. Commercial extraction of kava into capsules, shots, and Western bar franchises raises active questions about who benefits from a Pacific tradition and whether decontextualized products honor or strip the practice.
Where scholars disagree
Kava belongs to living Oceanic traditions with active sovereignty stakes. Vanuatu's kava legislation designates noble cultivars as national patrimony and restricts which varieties may be exported, and Pacific communities have voiced concern that Western capsules, shots, and bar franchises commercialize a ceremonial practice while detaching it from its protocols of rank, genealogy, and worship. Hawaii's 2025 affirmation of ʻawa as a traditional Native food is part of a broader reassertion of Pacific control over the plant.
Researchers agree kava can rarely cause serious liver injury but disagree about why, framed historically as the Pacific kava paradox. One camp attributes harm chiefly to Western solvent extraction; another attributes it to raw-material quality, cultivar, and plant part. The clinical anxiety finding is not in dispute; only the toxicity mechanism is.
Original Pacific kava paradox proponents (early 2000s)
Hepatotoxicity is largely a product of Western ethanolic and acetonic extracts, while traditional water-based Pacific preparation is essentially safe.
What it rests onEarly case clustering around organic-solvent commercial extracts, and the historical scarcity of reported liver injury in traditional aqueous use, formed the basis of the German 2002 action against ethanolic and acetonic products.
Raw-material-quality researchers (Schmidt, Teschke and colleagues, c.2011 to 2015)
Solvent type is not the decisive factor; harm tracks poor raw material, including mold-derived toxins, non-noble two-day (tudei) cultivars, and use of aerial parts with higher flavokavain B, with aqueous extracts also implicated.
What it rests onDocumented liver-injury cases involving traditional aqueous extracts from New Caledonia, Australia, the USA, and Germany, plus laboratory work on flavokavain B and mold contamination, were cited by the German court that overturned the ban in 2014.
At a glance
- Oldest documented origin
- Domesticated ~3,000 years ago in northern Vanuatu from wild Piper wichmannii; seedless and propagated only by cuttings
- Active compounds
- Kavalactones (kavain, dihydrokavain, methysticin, yangonin), concentrated in root and rhizome
- Best-supported use
- Short-term anxiety; the 2003 Cochrane review of double-blind RCTs reported a significant but modest HAM-A reduction
- Key safety driver
- Rare serious liver injury; reviewers report risk tracks poor-quality material, aerial parts, tudei cultivars, solvents, and alcohol co-use
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Kava. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What people take it for. We have not catalogued the claims made for it.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.